November 17, 2016 - By Pete Kolinski · 0 Comments
The stock of SEVION THERAPEUTICS INCORPORATED (OTCMKTS:SVON) registered a decrease of 5.56% in short interest. SVON’s total short interest was 1,700 shares in November as published by FINRA. Its down 5.56% from 1,800 shares, reported previously. With 8,600 shares average volume, it will take short sellers 0 days to cover their SVON’s short positions. The stock increased 14.29% or $0.02 on November 16, hitting $0.16. About 880 shares traded hands. Sevion Therapeutics Inc (OTCMKTS:SVON) has declined 30.43% since April 15, 2016 and is downtrending. It has underperformed by 35.06% the S&P500.
Sevion Therapeutics, Inc. is a development-stage biotech company. The company has a market cap of $3.30 million. The Firm is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. It currently has negative earnings. The Firm is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies.
Sevion Therapeutics, Inc., incorporated on September 30, 1999, is a development-stage biotech company. The Firm is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Firm is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages.
More notable recent Sevion Therapeutics Inc (OTCMKTS:SVON) news were published by: Businesswire.com which released: “Sevion Therapeutics Announces Immuno Oncology Discovery Program at BIO” on June 16, 2015, also Businesswire.com with their article: “Harlan Waksal, M.D. resigns as Chairman of the Board of Sevion Therapeutics” published on March 11, 2016, Seekingalpha.com published: “Interview With Fabrus President Dr. Vaughn Smider” on January 14, 2014. More interesting news about Sevion Therapeutics Inc (OTCMKTS:SVON) were released by: Seekingalpha.com and their article: “Senesco Technologies: A Potential $26 Stock Trading At $5” published on November 04, 2013 as well as Businesswire.com‘s news article titled: “Tetragenetics Launches Partnership Program For Discovery and Development of …” with publication date: December 17, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski